AI-assisted telerehabilitation in early Parkinson’s disease: a multicenter, randomized, multi-arm comparative trial

Abstract This exploratory, multicenter, randomized, rater-blinded, multi-arm comparative trial aimed to evaluate the feasibility and exploratory clinical signals of an AI-facilitated telerehabilitation system across different intervention durations in early-stage Parkinson’s disease (PD). One-hundred and twenty PD patients (Hoehn-Yahr stage ≤2.5) were randomized in a 1:1:1 ratio into short-term (1 month), medium-term (2 months), and long-term (3 months) training groups (15–30 min, 5 days/week). The primary outcome was the change in MDS-UPDRS Part III score from baseline to 3 months. Secondary outcomes included change in cognition, mood, gait parameters, activity of daily living, and safety. Final analysis included 71 participants. No significant differences were observed between groups for the primary motor outcome at 3 months. Post hoc responder analysis showed that the 3-month group had higher proportions reaching the exploratory cognitive responder threshold compared with the 1-month group. Exploratory correlations between MoCA changes and motor parameter changes were weak and did not remain statistically significant after false discovery rate correction. No falls or adverse events were recorded throughout the trial. Because the primary endpoint was negative, attrition was high, no usual-care control was included, and the cognitive finding was limited to an exploratory post-hoc responder analysis, these findings do not permit causal inference and should be interpreted as hypothesis-generating, requiring further validation in larger, prespecified multi-arm comparative trials (Chinese Clinical Trial Registry Number: ChiCTR2500108323).

Authors

Publication Details

Journal
npj Digital Medicine
Published
2026-10-07
DOI
https://doi.org/10.1038/s41746-026-03339-1
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

AI-assisted telerehabilitation in early Parkinson’s disease: a multicenter, randomized, multi-arm comparative trial

Yunfei Long, 黄建平, Wenyi Kou, Wen Su et al.
npj Digital Medicine
Parkinson's Disease Mechanisms and Treatments
article

AI-assisted telerehabilitation in early Parkinson’s disease: a multicenter, randomized, multi-arm comparative trial

Yunfei Long, 黄建平, Wenyi Kou, Wen Su, Yueying Liu, Dongdong WU, Miaoxian Xie, Yi Wang, Kezhong Zhang, Shuhua Li, Huimin Chen, Wei Du, Jing He, Haibo Chen, Huijing Liu, Xinxin Ma, Xue Bai
article en

Abstract

Abstract This exploratory, multicenter, randomized, rater-blinded, multi-arm comparative trial aimed to evaluate the feasibility and exploratory clinical signals of an AI-facilitated telerehabilitation system across different intervention durations in early-stage Parkinson’s disease (PD). One-hundred and twenty PD patients (Hoehn-Yahr stage ≤2.5) were randomized in a 1:1:1 ratio into short-term (1 month), medium-term (2 months), and long-term (3 months) training groups (15–30 min, 5 days/week). The primary outcome was the change in MDS-UPDRS Part III score from baseline to 3 months. Secondary outcomes included change in cognition, mood, gait parameters, activity of daily living, and safety. Final analysis included 71 participants. No significant differences were observed between groups for the primary motor outcome at 3 months. Post hoc responder analysis showed that the 3-month group had higher proportions reaching the exploratory cognitive responder threshold compared with the 1-month group. Exploratory correlations between MoCA changes and motor parameter changes were weak and did not remain statistically significant after false discovery rate correction. No falls or adverse events were recorded throughout the trial. Because the primary endpoint was negative, attrition was high, no usual-care control was included, and the cognitive finding was limited to an exploratory post-hoc responder analysis, these findings do not permit causal inference and should be interpreted as hypothesis-generating, requiring further validation in larger, prespecified multi-arm comparative trials (Chinese Clinical Trial Registry Number: ChiCTR2500108323).

npj Digital Medicine
Openalex Percentile: Top 13%
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.